Unit

UNIT 5.60 Animal Models of Systemic Lupus Erythematosus (SLE) and Ex Vivo Assay Design for Drug Discovery

  1. Matthew M. Seavey,
  2. Lily D. Lu,
  3. Kristine L. Stump

Published Online: 1 JUN 2011

DOI: 10.1002/0471141755.ph0560s53

Current Protocols in Pharmacology

Current Protocols in Pharmacology

How to Cite

Seavey, M. M., Lu, L. D. and Stump, K. L. 2011. Animal Models of Systemic Lupus Erythematosus (SLE) and Ex Vivo Assay Design for Drug Discovery. Current Protocols in Pharmacology. 53:5.60:5.60.1–5.60.40.

Author Information

  1. Worldwide Discovery Research, Cephalon, Inc., West Chester, Pennsylvania

Publication History

  1. Published Online: 1 JUN 2011
  2. Published Print: JUN 2011

Abstract

Systemic Lupus Erythematosus (SLE) is a debilitating and often fatal autoimmune disease that involves multiple organ systems. It can develop for years before being diagnosed. Current treatments for SLE usually involve the use of cytotoxic or immunosuppressive agents that can lead to infection or cancer. The design of appropriate models and assays will determine the efficiency and speed with which an investigator can test a new chemical entity (NCE) or expect results to move a drug discovery program forward. This unit describes a series of preclinical assays for the identification of new agents for the treatment of SLE. Most importantly, this unit will guide the reader through a step-by-step process to select appropriate models, validation drugs, and readouts, depending on the objective of the study. The reader will acquire a working knowledge of what models are available and the potential advantages and disadvantages of each, including ex vivo assays relevant to the discovery of new SLE therapeutics. Curr. Protoc. Pharmacol. 53:5.60.1-5.60.40. © 2011 by John Wiley & Sons, Inc.

Keywords:

  • lupus;
  • SLE;
  • drug discovery;
  • animal models